A class action lawsuit has been initiated against gene therapy company uniQure N.V., alleging that corporate leadership made materially false and misleading statements regarding the FDA approval status of their Pivotal Study design and potential delays to their Biologics License Application (BLA) timeline. The litigation targets securities purchased during a specific window, raising questions about the accuracy of regulatory communications disclosed to the investment community.
The lawsuit encompasses investors who acquired uniQure securities between September 24, 2025 and October 31, 2025. According to the filing, shareholders contend they were not adequately informed about the risks associated with the regulatory pathway for the company's lead therapeutic candidates. The case represents a significant development in the biotech sector, where regulatory timelines and FDA feedback carry substantial weight in investor decision-making.
Prospective claimants have until April 13, 2026 to submit their claims as lead plaintiff in the action. The litigation underscores ongoing scrutiny of disclosure practices among biopharmaceutical companies navigating the complex FDA approval process. Investors who purchased shares during the specified period may be eligible to participate in the class action.